Repository logo
 
Publication

Controversies in myopia control treatment: what does it mean for future research?

2025-04Journal article Open access
Simple item page
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorLança, Carla
dc.contributor.authorRepka, Michael X.
dc.contributor.authorGrzybowski, Andrzej
dc.date.accessioned2025-01-15T13:23:18Z
dc.date.available2025-01-15T13:23:18Z
dc.date.issued2025-04
dc.description.abstractPurpose: Treatment of myopia has been informed by more than 3 decades of clinical trials and other observations. However, controversies regarding myopia control remain, such as when to stop treatment and what is the long-term efficacy of treatment. This perspective aims to describe clinically relevant and current controversies regarding myopia treatment. Design: Perspective. Methods: We reviewed clinical trial data and other studies regarding myopia control therapies. Results: Controversies in myopia treatment are related to the efficacy of low-dose atropine eyedrops and new lens design spectacles to reduce the progression of myopia substantially. In addition to efficacy, the safety of therapies including soft contact lenses, orthokeratology, and low-level red light remains a concern. The therapeutic role of outdoor time in reducing myopia progression also requires further investigation. More research is necessary to confirm treatment effectiveness, required treatment duration, tapering schedules, and when to begin and stop treatment. Conclusions: Myopia management is evolving and maintaining competency in the multiple approaches poses a challenge. Key challenges include identifying high-risk children who would benefit most from treatment, limited evidence supporting the effectiveness of myopia progression control treatments in certain populations, and concerns regarding the availability and cost of treatment, which may create socioeconomic barriers to access. The limitations of current methods to slow or stop myopia progression highlight the need for continuing rigorous investigation of new and improved strategies to reduce the burden of myopia.eng
dc.description.sponsorshipFunding/Support: No funding received. Financial Disclosures: Carla Lanca reports a relationship with Eyerising that includes: consulting or advisory. Michael X. Repka reports a relationship with National Eye Institute that includes: funding grants.
dc.identifier.citationLança C, Repka MX, Grzybowski A. Controversies in myopia control treatment: what does it mean for future research? Am J Ophthalmol. 2025;272:79-86.
dc.identifier.doi10.1016/j.ajo.2024.12.029
dc.identifier.pmid39793686
dc.identifier.urihttp://hdl.handle.net/10400.21/21303
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S0002939425000054
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectOphthalmology
dc.subjectMyopia
dc.subjectMyopia control
dc.subjectMyopia treatment
dc.titleControversies in myopia control treatment: what does it mean for future research?eng
dc.typejournal article
degois.publication.firstPage79
degois.publication.lastPage86
degois.publication.volume272
dspace.entity.typePublication
oaire.citation.titleAmerican Journal of Ophthalmology
oaire.versionhttp://purl.org/coar/version/c_ab4af688f83e57aa
person.familyNameLança
person.givenNameCarla
person.identifier.ciencia-id601A-6412-BF2F
person.identifier.orcid0000-0001-9918-787X
relation.isAuthorOfPublication0320b455-ee19-4670-8bf2-10dce9de1bec
relation.isAuthorOfPublication.latestForDiscovery0320b455-ee19-4670-8bf2-10dce9de1bec

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Controversies in myopia control treatment_what does it mean for future research.pdf
Size:
864.5 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos